Henko says it selected PopsiCube as it has a track of record successful projects in various therapeutic areas such as oncology, rare diseases, and cardiovascular disease, The company, it says, has a track record of successful projects in areas including oncology, rare diseases, and cardiovascular disease. Henko says it has used it subsidiary MissionTEC to develop strategies for decentralized clinical trials which have become more and more important in recent years.
Last July (2022), Henko had already invested in BioClever, a Spanish CRO, with expertise in biometrics. Henko says that starting with these three investments, it is building a pan-European CRO that will offer a wider range of clinical trials services to its customers and in turn, their patients.
Henko Partners says it will support the international expansion of the companies and create a European CRO that offers clients access to cross-country services, in addition to continuing to service national markets. The new European CRO will be able to manage all aspects of clinical trials, from early to late phase studies and including decentralized clinical trials.
The founders and current management team of PopsiCube will continue to lead the company. Henko will provide operating support alongside capital to accelerate the business plan.
"This is an exciting opportunity for us," said Fabrice Beauchêne, CEO of PopsiCube. "Henko's expertise and resources will enable us to enhance our service offering while continuing to provide our clients with the same reliable quality they know."
PopsiCube is a French-based CRO that offers end-to-end services for clinical trials. The company has almost 20 years of experience in providing clinical research services to clients in the pharmaceutical, biotech, and medical device industries.
The companies say the partnership with Henko Partners, PopsiCube, MissionTEC, and BioClever is a big step towards creating a comprehensive solution for the European life science industry. They believe the new venture places the companies in an ideal position to take advantage of the extensive growth opportunities present in the CRO industry across Europe.
Henko says that after investing in Spain and France with these three companies, it intends to continue investing in CROs across Europe to form a leading company that focuses on high-quality and innovative services for clinical research.
"PopsiCube and MissionTEC have established strong reputations as leaders in their respective fields," said Lars Becker, partner at Henko. "We are thrilled to help them grow their business by providing support and resources."
MissionTEC is a CRO that specializes in providing clinical research nursing services and investigator's site supports. The company has a strong presence in Europe, with a network of experienced clinical research nurses who provide innovative solutions for clinical research studies.
Henko Partners was advised in this transaction by Bird&Bird and Oderis as legal and financial advisors, respectively.
